CVS Health Trades Cheaper Than Industry: How to Play the Stock?

CVS Health (CVS) is presented as an attractively valued investment, trading at a forward price-to-sales (P/S) ratio of 0.23, significantly below its industry and peer averages, despite a 64.2% year-to-date stock gain. This favorable valuation is supported by strategic progress across its diversified model, including Aetna's stabilization through Medicare gains and AI-driven enhancements, the Pharmacy & Consumer Wellness segment's improved reimbursement transparency via the CostVantage model, and a substantial $20 billion commitment to a digital-first, tech-enabled healthcare strategy focused on interoperability. Analysts have concurrently raised earnings estimates, projecting a nearly 17% EPS jump for 2025, reinforcing the positive outlook.

Analysis

CVS Health presents a compelling case based on a combination of attractive valuation, strong operational execution, and a clear strategic vision. The stock trades at a significant discount with a forward price-to-sales ratio of 0.23, which is below its own median of 0.29 and substantially lower than the industry average of 0.41 and peer UnitedHealth Group's 0.61. This valuation exists despite a 64.2% year-to-date stock surge that has outperformed the industry and rivals. The momentum is underpinned by progress across its diversified segments. The Aetna insurance arm is stabilizing, showing Medicare gains driven by improved star ratings and a strategic exit from underperforming ACA plans set for 2026. Simultaneously, the Pharmacy & Consumer Wellness segment is addressing reimbursement pressures with its new CostVantage model, which transitions to a more transparent, cost-based pricing structure. This operational strength is complemented by a forward-looking, $20 billion, decade-long investment in a digital-first strategy to enhance interoperability and the consumer health experience. This positive outlook is quantitatively supported by upward analyst revisions, with the Zacks Consensus Estimate for 2025 EPS rising 3.9% in the past 90 days to $6.34, implying a nearly 17% year-over-year increase.

Key Decisions for Investors

• Given the stock's discounted P/S ratio of 0.23 relative to peers and its own history, alongside upwardly revised EPS forecasts, investors may see the current valuation as a favorable entry point, especially in light of its 64.2% YTD outperformance.
• Monitor key execution milestones, particularly the financial impact of the CostVantage model on pharmacy margins and the progress of Aetna's product rationalization, as these are central to the investment thesis.
• Consider the $20 billion technology commitment as a long-term catalyst for creating a competitive moat, but remain watchful for early indicators of return on invested capital to validate the strategy's effectiveness.
• For those with sector-wide exposure, it may be prudent to evaluate re-weighting portfolios toward CVS, given its current combination of relative value, operational momentum, and strong stock performance compared to peers like UNH and CI.